Chemomab Therapeutics Ownership | Who Owns Chemomab Therapeutics?

Chemomab Therapeutics Ownership Summary

Chemomab Therapeutics is owned by 1.15% institutional investors, 15.27% insiders, and 83.58% retail investors.

CMMB Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Chemomab Therapeutics	1.15%	15.27%	83.58%
Sector	Healthcare Stocks	279.19%	10.58%	-189.76%
Industry	Biotech Stocks	63.97%	10.68%	25.35%

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2025	17	6.25%	3,731,679	-10.31%	1	69.98%	9	50.00%	3	-50.00%
Dec 31, 2024	16	6.67%	4,160,723	-8.55%	1	76.12%	6	-40.00%	6	500.00%
Sep 30, 2024	15	-	4,549,767	70.23%	1	148.65%	10	100.00%	1	-66.67%
Jun 30, 2024	15	7.14%	2,672,756	0.42%	-	106.48%	5	25.00%	3	50.00%
Mar 31, 2024	14	-17.65%	2,661,598	-5.57%	-	79.88%	4	-50.00%	2	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jan 03, 2023	OrbiMed Israel GP Ltd.	-	Sell	$318.06K
Jan 03, 2023	OrbiMed Israel GP Ltd.	-	Sell	$889.70K
Jan 03, 2023	Mor George Adi	Chief Scientific Officer	Sell	$38.71K
Jan 03, 2023	Mor George Adi	Chief Scientific Officer	Sell	$30.66K
Nov 16, 2022	Cohen Neil Harris	-	Sell	$4.82K

Insider Transactions Trends

Date	Buy	Sell
2023 Q2	-	-
2023 Q1	-	4
2022 Q4	-	3
2022 Q2	2	-
2022 Q1	6	-

CMMB Ownership FAQ

Who Owns Chemomab Therapeutics?

Chemomab Therapeutics shareholders are primarily institutional investors at 1.15%, followed by 15.27% insiders and 83.58% retail investors. The average institutional ownership in Chemomab Therapeutics's industry, Biotech Stocks , is 63.97%, which Chemomab Therapeutics falls below.

Does Blackrock own Chemomab Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Chemomab Therapeutics.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools